Platelet transfusion requirements are higher among patients with veno-occlusive disease (VOD), compared to patients without VOD. One possible explanation is inadequate production of thrombopoietin (TPO), a protein synthesized in the liver. We prospectively studied 28 patients to test the hypothesis that plasma TPO levels were decreased in patients who developed VOD. Plasma TPO levels to day +30 were measured by ELISA (normal, 0.36 ؎ 0.15 fmol/ml). VOD developed in 18/28 patients. Platelet transfusion requirements were significantly different in patients with and without VOD (97 ؎ 46.1 units vs 51 ؎ 33.2 units, P = 0.008). Plasma TPO levels were elevated at baseline (10.8 ؎ 13.0 fmol/ml) and increased after transplant, with peak values of 32.3 ؎ 10.3 fmol/ml at day +7. TPO levels were significantly higher at days +7 and +17 among patients with VOD than among those without VOD (P Ͻ 0.01). Regression analysis of TPO levels vs platelet counts showed a significant inverse relationship. We conclude that TPO levels were higher in patients with VOD and were inversely correlated with platelet counts, suggesting that regulation of TPO levels was related to platelet mass. Thrombocytopenia in patients with VOD cannot be explained by inadequate hepatic synthesis of TPO.
among patients with VOD, compared to patients without VOD. 3, 4 Transfusion requirements are highest in patients with more severe VOD.
The mechanisms for thrombocytopenia in patients with VOD are not well understood. There are three possibilities: underproduction of platelets, more rapid destruction, or a combination of these. Cytoreductive therapy greatly reduces host megakaryocytes and platelet production is decreased until engraftment of donor platelet progenitor cells. Thrombocytopenia is therefore an expected consequence of myeloablative therapy, but patients with VOD require more transfused platelets than patients who do not develop VOD, suggesting that there is increased destruction of platelets in the early phases of VOD. However, even after engraftment, patients with VOD often remain thrombocytopenic. 3 One possible explanation is inadequate production of thrombopoietin, a protein synthesized predominantly in the liver 5 and the most important physiological regulator of platelet homeostasis. 6 Several investigators have reported increased blood levels of TPO following hematopoietic stem cell transplantation. [7] [8] [9] However, one report noted significantly lower TPO levels after transplant among patients with VOD, compared to patients without VOD. 7 This finding is contrary to what might be predicted from the localization of intrahepatic synthesis of TPO to periportal hepatocytes 5 that are spared in patients with VOD. 2 We prospectively followed 28 patients undergoing marrow transplantation to further test the hypothesis that thrombopoietin levels were decreased in patients who developed VOD.
Materials and methods

Marrow transplantation
The technique of marrow transplantation used at the Fred Hutchinson Cancer Research Center has been published. 10 Briefly, patients receive cytoreductive therapy before infusion of donor marrow on day 0. The specific regimens received by these patients are described in the Results section. Allogeneic marrow recipients received cyclosporine and methotrexate to prevent acute graft-versus-host disease.
Patient selection and the blood sampling protocol
We selected patients for this study on the basis of an increased risk of VOD, that is, increased serum aspartate aminotransferase (AST) before transplant, or a regimen of cytoreductive therapy known to cause VOD, or a second transplant. Patients agreed to have blood samples drawn under a protocol approved by the Institutional Review Board of the Fred Hutchinson Cancer Research Center. Blood was drawn between 5 and 8 am from central venous access catheters at baseline and frequently thereafter for blood counts and a panel of chemistries. At baseline, during conditioning therapy on days Ϫ7 and day Ϫ1, and after transplant on days +7, +17, +25 and +30, blood was collected over sodium citrate, centrifuged, and the plasma stored at Ϫ80°C before shipment on dry ice to Chiba, Japan, for measurement of thrombopoietin levels.
Measurement of thrombopoietin
Plasma TPO levels were measured by a sandwich enzymelinked immunosorbant assay, as previously described. 11 Briefly, the assay uses two anti-recombinant human TPO antibodies, with a mouse neutralizing monoclonal antibody as the capture and a biotinylated rabbit polyclonal F(abЈ) 2 antibody as the detection antibody. The wells of microtiter plates were coated with 100 l of the capture antibody at a concentration of 10 g/ml. After preincubation of the wells with 200 l of a blocking reagent, 100 l of either rhTPO standard or plasma was added to each well and reacted with the coated antibody. After washing, 100 l of the detection antibody at 500 ng/ml was added to each well for 3 h. After washing, 100 l of streptavidin-alkaline phosphatase conjugate (1 mU/ml) was added. The bound conjugate was detected by using an amplification system (Gibco BRL, Gaithersberg, MD, USA) and reading the extinction at 492 nm. The concentration of TPO in each plasma sample was calculated by regression analysis from the standard curve. In this ELISA system, plasma TPO levels in 20 healthy volunteers were 0.36 Ϯ 0.15 fmol/ml (range 0.12-0.69), approximately equivalent to 12.96 Ϯ 5.4 pg/ml.
Diagnosis of VOD
The diagnosis of VOD was based on previously published criteria that take into account weight gain, hepatomegaly, hepatic pain and jaundice. 3 Patients who met criteria for VOD were further classified as mild, moderate or severe, using criteria based on the clinical impact of the VOD and whether or not it was reversible. 3 
Statistical methods
Values for thrombopoietin, platelet counts, platelet transfusion requirements,and total serum bilirubin at specific points in time were compared among patients with and without VOD using the Mann-Whitney U test. The relationship between platelet counts and thrombopoietin levels was examined by transforming the data logarithmically and performing a linear regression of log-transformed data (Statview, Abacus Concepts, Berkeley, CA, USA). No adjustments for multiple comparisons were made in these analyses.
Results
Patient characteristics
Twenty-eight patients were studied, 20 males and eight females, average age 36.4 Ϯ 11.7 years (range 19-56 years). The underlying diagnoses included chronic myeloid leukemia (n = 10), acute myeloid leukemia (n = 10), acute lymphocytic leukemia (n = 3), myelodysplastic syndrome (n = 3) and non-Hodgkin's lymphoma (n = 2).
Conditioning regimens and transplant donors
A regimen of cyclophosphamide 120 mg/kg plus total body irradiation (13.2-13.4 Gy) was given to 22 patients. Five patients received busulfan 16 mg/kg plus cyclophosphamide 120 mg/kg. One patient received cyclophosphamide 120 mg/kg plus total body irradiation (12 Gy). All patients received marrow from allogeneic donors, 17 of whom were HLA matched and 11 were HLA mismatched.
VOD
A diagnosis of VOD was made in 18/28 patients. VOD was scored as mild in eight patients, moderate in seven patients and severe in three patients. Total serum bilirubin levels for 18 patients with and 10 without VOD are given in Table 1 .
TPO TPO levels at baseline were 10.8 Ϯ 13.0 fmol/ml. During conditioning therapy at day Ϫ7, TPO levels were 12.1 Ϯ 13.7 fmol/ml (P = 0.59, compared to baseline). All subsequent values were statistically significantly higher than baseline values (for each comparison, P Ͻ 0.001): at day Ϫ1, 24.0 Ϯ 14.3 fmol/ml; at day +7, 32.3 Ϯ 10.3 fmol/ml; at day +17, 30.7 Ϯ 15.2 fmol/ml; at day +25, 22.4 Ϯ 13.7 fmol/ml and at day +30, 24.4 Ϯ 15.7 fmol/ml. TPO levels were significantly higher post transplant in patients who developed VOD, compared to those without VOD (Table 1 and Figure 1 ). 3 . Although mean platelet counts were lower in patients with VOD at each post-transplant time period, the differences were not statistically different from values in patients without VOD (Table 1) . Platelet transfusion requirements, however, were significantly higher among patients with VOD than among patients without VOD. From the start of cytoreductive therapy to day 30 post transplant, patients who developed VOD received 97 Ϯ 46.1 platelet units, compared to 51 Ϯ 33.2 platelet units for patients without VOD (P = 0.008). The relationship between TPO levels and platelet counts from the same mornings (before infusion of platelets) showed a significant inverse relationship. This relationship was almost identical in patients with and without VOD ( Figure  2 ), suggesting that TPO levels were being physiologically regulated by the platelet mass.
Platelet counts
Discussion
This prospective study shows that patients with hematologic malignancy had TPO plasma levels at baseline that were higher than in normal healthy controls, and that TPO levels rose progressively in the first 17 days post allogeneic transplant, coincident with decreases in platelet counts. Contrary to our stated hypothesis and a recent report, 7 the levels of TPO were higher in patients who developed VOD than in those who had no signs or symptoms of VOD, suggesting that hepatic synthesis of TPO remained intact despite extensive injury in the centrilobular area of the liver. 2 This result is consistent with recent observations that hepatocytes in zone 1 of the liver acinus (the periportal region) are the primary intrahepatic site of synthesis of TPO. 5 Preservation of hepatic synthesis of TPO may be important in the transplant setting if conditioning therapy has damaged marrow and splenic sites of TPO synthesis. A significant percentage of total TPO synthesis also arises from the proximal convoluted tubules of the kidney, 5 but the contribution of a renal tubular site of synthesis in patients with VOD might be questioned because of evidence for extensive tubular necrosis in these patients. 12 Maintenance of blood TPO levels has been noted among patients with chronic liver disease, cirrhosis and portal hypertension, as long as patients were not in hepatic failure. 13 In our study, the relationship between platelet counts and TPO levels was an inverse one, just as in normal experimental animals in whom the platelet mass appears to directly regulate circulating levels of TPO.
14 Similar findings in marrow transplant patients have been noted by other investigators. 7, 8 These findings suggest that the physiologic control of circulating TPO is intact after conditioning therapy and allogeneic stem cell transplantation. The data are somewhat in conflict with recent observations that the megakaryocyte mass, reflected in the rate of platelet production, is the major determinant of TPO levels but consistent with reports of elevated TPO levels following cytoreductive therapy and stem cell transplantation. [15] [16] [17] However, in contrast to normal subjects, TPO levels in our patients were elevated at baseline and remained high post transplant, even though platelet counts tended to increase after platelet engraftment. Some investigators have hypothesized that a persistent defect of thrombopoiesis may exist in these patients before the start of conditioning therapy and elevated levels of endogenous TPO may be required to maintain normal counts in the circulation. 18 There are data in a murine model and in man to suggest that serum TPO levels may also be regulated by a feedback system that modulates TPO gene expression in the marrow and the spleen. 5, 19 In man, this feedback regulation appears to occur mostly in the marrow. 5, 19, 20 It is likely that an extremely hypocellular post transplant marrow, a small megakaryocyte mass, and preservation of other sites of TPO production contributed to relatively high TPO plasma levels after transplantation. 17, 21 It is unlikely that platelet transfusions during the afternoon and evening influenced the levels of TPO drawn the next morning, as TPO levels tend to decrease a few hours after platelet transfusions but then return to pretransfusion levels. 8 The reason behind the higher TPO levels in patients with VOD than in those without VOD is unknown, but is probably related to decreased platelet survival in the former group, as evinced by significantly higher platelet transfusion requirements. The recent report of lower TPO levels in patients with VOD, using an identical ELISA method for TPO, was based on data from only two patients. 7 During the time post transplant when there is minimal platelet production, persistent thrombocytopenia in patients with VOD is almost certainly caused by more rapid consumption of infused platelets. The mechanism for disappearance of platelets at this time is not known. Early electron microscopy studies suggested that platelets were enmeshed in extracellular matrix in the area of liver damage in animals with VOD, 22 but immunohistochemical studies of liver tissue from marrow transplant patients with VOD showed no evidence of platelet antigens in this area. 23 However, the half-life of platelet antigens at the surface of damaged endothelial cells may be too short to be detected by morphometric methods. Another possibility is the pooling and destruction of platelets in the spleen. Patients with VOD develop portal hypertension, with portal pressures that are similar to those in patients with end-stage cirrhosis of the liver. 24, 25 There is no direct evidence, however, that platelets are sequestered in the spleen of patients with VOD.
Could elevated plasma TPO levels be a cause of decreased platelet survival? Although TPO alone is incapable of activating platelets, 26 one could argue that elevated TPO levels might effect platelet aggregration by priming platelets to become more sensitive to agonists of aggregration and release. [27] [28] [29] Necrosis of hepatocytes and endothelial cells within the liver in VOD and markedly abnormal sinusoidal blood flow could provide the required agonists to lead to platelet aggregration. In vitro, TPO primes platelets for the aggregration that is induced by collagen and thrombin and increases the velocity and extent of platelet aggregration induced by shear stress. 27 In patients with VOD, the propeptide of type III collagen is released into the circulation and microthromboses develop in the walls of terminal hepatic venules. 23 Shear stress in partly occluded blood vessels is a well-described stimulus to platelet aggregration, 30 a situation that may well pertain in VOD. Against the hypothesis that elevated TPO levels might cause platelet aggregration is the observation that exogenous TPO did not increase thrombotic events in segments of endarterectomized aorta and vascular grafts in baboons. 31 In conclusion, this study demonstrates that TPO levels are elevated after marrow transplant, being higher in those who develop VOD. Synthesis of TPO, which remains intact despite severe liver dysfunction, appears to be physiologically regulated by the platelet mass. The mechanisms for increased platelet transfusion requirements in patients with VOD remain unknown.
